SCHEMBL2970360

SCHEMBL2970360

Cc1ccc2c(Nc3ccc(Oc4ccc(Cl)cc4)c(Cl)c3)ccnc2n1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.47
SCN5A Q14524 1/20 0.47
GRM4 Q14833 1/20 0.45
PNLIP P16233 8/20 0.41
P2RX3 P56373 1/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SLC2A1 P11166 1/20 0.39
IGF1R P08069 1/20 0.39
GAK O14976 1/20 0.39
S1PR4 O95977 1/20 0.39
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2955700 0.80 IGF1R (0.45) SCN9ASCN5AMAPTIGF1RGAK
SCHEMBL2968878 0.79 IGF1R (0.47) MAPTIGF1RSMN1; SMN2KDR
SCHEMBL2968548 0.79 IGF1R (0.42) SCN9ASCN5AMAPTIGF1RGAK
SCHEMBL2955707 0.78 IGF1R (0.41) SCN9ASCN5AP2RX3MAPTIGF1R
SCHEMBL2970983 0.78 NR4A2 (0.42) SCN9ASCN5AP2RX3MAPTIGF1R
SCHEMBL2957627 0.77 IGF1R (0.40) SCN9ASCN5AMAPTIGF1RGAK
SCHEMBL2968819 0.75 IGF1R (0.45) SCN9AMAPTIGF1RSMN1; SMN2NPC1
SCHEMBL2961143 0.75 IGF1R (0.40) SCN9ASCN5AMAPTNPSR1IGF1R
SCHEMBL8328406 0.73 PDE10A (0.46) P2RX3MAPTNPSR1IGF1R
SCHEMBL2964444 0.73 RIPK2 (0.39) MAPTIGF1RTP53KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024057740-A1 TREATMENT AGENT FOR ACRYLIC FIBERS AND USE OF SAME 松本油脂製薬株式会社 2024-03-21 WO disclosed
CN-107994269-B Lead-carbon battery with high cycle times and preparation method thereof 江苏华富储能新技术股份有限公司 2024-01-30 CN disclosed
US-20230375291-A1 CIRCULATING COOLING WATER TREATMENT METHOD AND COOLING PERFORMANCE IMPROVEMENT METHOD KURITA WATER INDUSTRIES LTD. (JP) 2023-11-23 US disclosed
EP-4230949-A1 CIRCULATING COOLING WATER TREATMENT METHOD AND COOLING PERFORMANCE IMPROVEMENT METHOD Kurita Water Industries Ltd. (JP) 2023-08-23 EP disclosed
CN-116478494-A Sealing composition, method for producing same, and sealing sheet 味之素株式会社 2023-07-25 CN disclosed
CN-116194623-A Method for cleaning aluminum nitride single crystal substrate, method for producing aluminum nitride single crystal laminate, method for producing aluminum nitride single crystal substrate, and aluminum nitride single crystal substrate 株式会社德山 2023-05-30 CN disclosed
US-20210310187-A1 ARTIFICIAL LEATHER FOR AUTOMOTIVE INTERIOR MATERIALS AND METHOD OF MANUFACTURING THE SAME LG HAUSYS, LTD. (KR) 2021-10-07 US disclosed
CN-110541228-B Moisture-absorbing dry textile fabric 江苏大毛牛新材料有限公司 2021-08-10 CN disclosed
US-20210222361-A1 ARTIFICIAL LEATHER FOR AUTOMOTIVE INTERIOR MATERIALS AND METHOD OF MANUFACTURING THE SAME LG HAUSYS, LTD. (KR) 2021-07-22 US disclosed
CN-107994230-B Lithium iron phosphate cathode material and preparation method thereof 华富(江苏)锂电新技术有限公司 2021-02-26 CN disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
EP-1013258-B1 Amphipatic lipid dispersion KAO CORP (JP) 2008-08-20 EP disclosed
EP-1093800-B1 Cosmetic composition KAO CORP (JP) 2007-12-19 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed
US-6830754-B2 Amphipatic lipid containing a hydroxy and amide group; and of a surfactant in an aqueous medium; a washing-away type cosmetic composition comprising the dispersion KAO CORPORATION (JP) 2004-12-14 US disclosed
US-20020058052-A1 AMPHIPATIC LIPID DISPERSION KAO CORPORATION (JP) 2002-05-16 US disclosed
EP-1093800-A2 Cosmetic composition Kao Corporation (JP) 2001-04-25 EP disclosed
EP-1013258-A2 Amphipatic lipid dispersion Kao Corporation (JP) 2000-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 SCN9A 3852/4885SCN5A 4400/4885GRM4 4383/4885
US-20020058052-A1 AMPHIPATIC LIPID DISPERSION LIPA, MGLL, CUTA SCN9A 2743/4885SCN5A 1424/4885GRM4 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.